Elicio Therapeutics, Inc. (ELTX)

NASDAQ: ELTX · IEX Real-Time Price · USD
7.80
+0.34 (4.56%)
Mar 28, 2024, 1:35 PM EDT - Market open

Company Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.

The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.

It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.

The company is headquartered in Boston, Massachusetts.

Elicio Therapeutics, Inc.
Elicio Therapeutics logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Robert T. Connelly

Contact Details

Address:
One Kendall Square, Building 1400 West, Suite 14303
Cambridge, Massachusetts 02139
United States
Phone 857-209-0056
Website elicio.com

Stock Details

Ticker Symbol ELTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001555192
ISIN Number US28657F1030
Employer ID 45-2966790
SIC Code 2834

Key Executives

Name Position
Robert T. Connelly Chief Executive Officer, President and Director
Dr. Christopher M. Haqq M.D., Ph.D. Executive Vice President, Head of Research and Development and Chief Medical Officer
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board
Brian Piekos Chief Financial Officer
Michael DiVecchia Senior Vice President of Operations and Human Resources
Dr. Peter DeMuth Ph.D. Chief Scientific Officer
Megan C. Filoon General Counsel, Secretary and Compliance Officer
Esther Welkowsky Senior Vice President of Clinical Development
Joy Seymour Vice President and Head of Regulatory Affairs
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics

Latest SEC Filings

Date Type Title
Nov 2, 2022 D/A Filing
Sep 13, 2022 RW Filing
May 27, 2022 D Notice of Exempt Offering of Securities
Nov 18, 2021 D/A Filing
Nov 12, 2021 D/A Filing
Oct 19, 2021 D Notice of Exempt Offering of Securities
Jul 13, 2021 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 29, 2021 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 28, 2021 S-1 General form for registration of securities under the Securities Act of 1933
Jun 9, 2021 DRS/A [Amend] [Cover] Draft Registration Statement